TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers linked lower levels of the protective protein NRF2 in oligodendrocytes to abnormal myelin, fewer large nerve fibers and faster cognitive decline. Mouse experiments support a possible role for NRF2 in these changes, but the study does not show that an NRF2-targeting drug prevents age-related decline in people.
A study published in Nature Medicine links dysfunction in oligodendrocytes—brain cells that maintain the insulating coating around nerve fibers—to faster cognitive decline with age. Researchers from the University of Edinburgh and the UK Dementia Research Institute found related changes in human brain tissue and reproduced key features in mice, identifying the cell-protective protein NRF2 as a possible target for future research, not a proven treatment for older adults.
The human findings came from the Lothian Birth Cohort 1936, whose participants have had cognitive abilities tracked from childhood into old age. Between ages 70 and 82, researchers assessed memory, processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional cognitive testing after age 70. Most experienced some decline, but the rate differed across participants.
In brain tissue collected after participants died, greater decline was associated with fewer large nerve fibers and an abnormal buildup of myelin, the fatty coating that helps electrical signals travel along nerve fibers. The association concerned the rate of decline over time, rather than a person’s cognitive test performance at a single age. This observational finding does not by itself establish that myelin changes caused the decline.
Researchers also found lower levels of NRF2 in oligodendrocytes among people with more severe decline. In mice, selectively reducing NRF2 in those cells led to excessive myelin, loss of large nerve fibers and less improvement in cognitive performance as the animals aged. The experiments support a direct role for NRF2 in the cell changes in mice, but they cannot establish that the same process accounts for cognitive decline in humans.
A New Lead in Myelin Damage
The work challenges the simple view that oligodendrocytes are always protective. These cells are needed to maintain myelin, but the findings suggest that their function can change with age and that abnormal myelin may accompany damage to nerve fibers. That offers researchers a potential biological pathway to investigate alongside other processes involved in cognitive aging.
The proposed pathway also has a possible connection to existing medicines: NRF2 is already targeted by drugs used for some neurological conditions, including multiple sclerosis. The study authors point to this as a reason to explore whether related treatments could be useful. It does not show that an existing medicine prevents or reverses age-related cognitive decline, and any such use would require evidence from further studies.
As an affiliate, we earn on qualifying purchases.
Tracking Cognitive Change Over Time
The cohort’s long record of cognitive testing gave researchers a way to compare brain tissue with changes in thinking abilities over many years. The analysis focused not only on test scores in later life, but on how quickly participants’ abilities changed between ages 70 and 82. Post-mortem tissue analysis then allowed the team to examine nerve fibers, myelin and oligodendrocytes in a subset of participants.
The researchers followed up the human observations with experiments that altered NRF2 in oligodendrocytes in mice. This combination offers evidence from both human tissue and an animal model, but each contributes different information: the cohort shows an association in people, while the mouse experiments test what happens when NRF2 is reduced under experimental conditions. Neither establishes the benefits or safety of treatment in older adults.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
As an affiliate, we earn on qualifying purchases.
From Mouse Results to Human Treatment
The research does not establish whether reduced NRF2 activity is a cause of cognitive decline in people, a consequence of other age-related changes, or part of a more complicated process. The human tissue findings are associations, and the mouse experiments cannot fully reproduce the course of aging and cognitive change in humans.
It is also not yet clear whether boosting NRF2 would protect cognition in older adults, which patients might benefit, or what risks or side effects treatment could carry. The report identifies drugs that act on the pathway as a possible research lead; it does not report a clinical trial demonstrating benefit for age-related cognitive decline.
cognitive decline support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the NRF2 Treatment Pathway
Further research will need to clarify how NRF2 loss changes oligodendrocyte function and whether those changes can be prevented or reversed. A key next step is testing whether medicines that influence the pathway produce a measurable benefit in relevant models, followed by carefully designed human studies if the evidence supports them.
Until such studies are reported, the findings should be treated as an explanation scientists are investigating rather than a basis for treatment. The immediate development is the identification of a possible link between oligodendrocyte dysfunction, myelin abnormalities and cognitive decline—not evidence that an available drug can slow cognitive aging.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which brain cells did the researchers study?
The study focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers.
What role did NRF2 appear to play?
NRF2 helps regulate cellular defenses and normal cell function. Researchers found lower NRF2 levels in oligodendrocytes in people with more severe decline; reducing it in mouse oligodendrocytes produced related myelin and nerve-fiber changes.
Does the study show that an existing drug prevents cognitive decline?
No. The researchers identified the NRF2 pathway as a possible treatment target, but the study did not test an NRF2-targeting drug as a treatment for age-related cognitive decline in people.
How were participants’ cognitive changes assessed?
Members of the Lothian Birth Cohort 1936 took assessments of memory, processing speed and spatial reasoning between ages 70 and 82. Researchers compared those changes with findings in brain tissue collected after death from a subset of participants.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
